The FDA approved resmetirom for the treatment of adults with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced liver fibrosis.
The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.
After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.
The FDA has expanded the approval of a new option for the treatment of adults and children aged 12 years or older or weighing at least 99 pounds with chronic hepatitis C virus genotypes 1, 2, 3, 4, 5, or 6...
The NHE3 sodium transport inhibitor was approved for use after results from 2 clinical trials showed increased bowel movements and decreased abdominal pain among individuals with IBS-C.
The FDA issued a drug safety warning after more than 60 individuals experienced liver injury after they received treatment with 1 of 3 medications for hepatitis C virus.
The FDA issued a safety alert after results of a safety clinical trial showed increased risk of blood clots and death with higher dosages of the janus kinase inhibitor.
